Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

remune

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

AIDS Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune
Objectives:Therapeutic HIV vaccination during the time of virologic suppression may delay or blunt viral load rebound after… 
2007
2007
Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine
Antibody responses against human leukocyte antigen (HLA) classes I and II were detected in HIV-1 infected individuals who… 
Highly Cited
2005
Highly Cited
2005
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
BACKGROUND Treatment strategies that would induce durable virological control of human immunodeficiency virus (HIV)-1 in the… 
  • figure 1
  • table 1
  • figure 3
  • table 2
  • table 3
2003
2003
Thymic output during initial highly active antiretroviral therapy (HAART) and during HAART supplementation with interleukin 2 and/or with HIV type 1 immunogen (Remune).
The thymic output of patients receiving highly active antiretroviral therapy (HAART) was assessed by sjTREC (signal joint T cell… 
2001
2001
Study Protocol for the Evaluation of the Potential for Durable Viral Suppression After Quadruple HAART With or Without HIV Vaccination: The QUEST Study
Abstract Purpose: By protecting and stimulating HIV-specific CD4 cell responses, treatment of primary HIV infection (PHI) with… 
2001
2001
The effects of an HIV‐1 immunogen (Remune) on viral load, CD4 cell counts and HIV‐specific immunity in a double‐blind, randomized, adjuvant‐controlled subset study in HIV infected subjects regardless…
Objective  We examined the activity of an HIV‐1 immunogen (Remune) on viral load, CD4 cells and HIV‐1 specific immunity. 
Review
2000
Review
2000
Sistemas de pago a prestadores de servicios de salud en países de América Latina y de la OCDE
The system used to pay health services providers is one of the most important components of the contractual relationship between… 
1998
1998
Safety and immunogenicity of REMUNE in HIV-infected Thai subjects.
The safety and immunogenicity of REMUNE, an HIV-specific immune based therapy for HIV infection, was evaluated in a cohort of 30… 
1997
1997
Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection.
OBJECTIVE To measure beta-chemokine and cytokine production in HIV-1-infected subjects undergoing treatment with HIV-1 immunogen… 
1997
1997
Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human…
Lymphocyte proliferation responses to gp120-depleted HZ321 virus (clade A) antigen were compared to BAL human immunodeficiency… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE